Centex

Cantex Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, well-tolerated oral treatments for cancer and inflammatory lung diseases. The company's lead candidate is azeliragon, a small molecule inhibitor of the Receptor for Advanced Glycation Endproducts (RAGE), which is being evaluated across multiple high-unmet-need indications including pancreatic cancer, glioblastoma, and brain metastases from breast cancer. Beyond oncology, Cantex is exploring the potential of azeliragon in treating severe inflammatory respiratory conditions such as COPD and asthma. Led by a team of experienced drug developers, the company aims to leverage its clinical assets to provide safer and more effective therapeutic options for patients with life-threatening diseases.